By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
DelMar Pharma Receives Approval From China's Human Genetic Resources Administration To Initiate Phase II Clinical Trial In Newly Diagnosed GBM 7/24/2017 7:27:02 AM
DelMar Pharma Announces Completion Of First Site Initiation Visit For STAR-3 Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM 7/18/2017 6:46:52 AM
DelMar Pharma Appoints Saiid Zarrabian To The Board Of Directors And Names Dr. Erich Mohr As Chairman 7/12/2017 10:08:26 AM
DelMar Pharma Appoints Saiid Zarrabian To The Board Of Directors And Names Dr. Erich Mohr As Chairman 7/11/2017 10:43:42 AM
DelMar Pharma Receives Institutional Review Board Approval For Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM 6/22/2017 7:26:49 AM
DelMar Pharma Presents Poster Of Clinical Research With VAL-083 In Patients With Chemo-Resistant Glioblastoma ("GBM") At SNO's Pediatric Neuro-Oncology Basic And Translational Research Conference 6/16/2017 6:45:28 AM
DelMar Pharma Announces Third Quarter Fiscal Year 2017 Financial Results 5/19/2017 8:45:47 AM
DelMar Pharma Formalizes Collaboration With PRA Health Sciences For Phase III Trial Of VAL-083 In Recurrent Glioblastoma Multiforme (GBM) 5/11/2017 7:41:21 AM
DelMar Pharma Presents New Mechanism Of Action Data For Its Lead Agent VAL-083 In Temozolomide-Resistant Glioblastoma Multiforme (GBM) At The World Federation Of Neuro-Oncology Societies (WFNOS) 5/8/2017 7:34:39 AM
DelMar Pharma Collaborates With Duke University To Explore VAL-083 As A Front-Line Treatment For Glioblastoma Multiforme 4/25/2017 7:26:37 AM
12345678910...
//-->